Abstract

The present invention addresses the problem of providing a technique for improving the antibody-inducing ability of a nasal vaccine, and a composition for nasal administration having improved antibody-inducing ability. The problem is solved by a composition for nasal administration containing: at least one substance selected from the group consisting of antigen polypeptides and polynucleotides including a coding sequence of an antigen polypeptide; and a sugar component that is a sugar and/or a sugar alcohol, wherein the content of the sugar component is more than 4.5% by mass/volume.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/10 - DispersionsEmulsions
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 35/761 - Adenovirus
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 31/12 - Antivirals
• A61P 33/00 - Antiparasitic agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a composition for use in vaccines, the composition containing a cationic lipid represented by formula (1).

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

The present invention can provide an Enterovirus-derived VLP vaccine that is safe and has a high stability. The VLP vaccine of the present invention is safe because of using, as an antigen, VLPs free from internal genes of the virus. The VLP vaccine has a high safety because of being fixed in formaldehyde at a high salt concentration.

IPC Classes  ?

• A61K 39/125 - Picornaviridae, e.g. calicivirus
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/06 - Inactivation or attenuationProducing viral sub-units by chemical treatment

Abstract

The purpose of the present invention is to provide a composition having higher efficacy and safety and suitable for use as a RS virus vaccine.　Provided is a composition containing G protein and a CpG oligodeoxynucleotide of a RS virus, in which the G protein does not have a modified sugar chain of a mammalian cell-expressed type.

IPC Classes  ?

• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 9/08 - Solutions
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/08 - RNA viruses
• C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses

Abstract

The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. The present invention contains the fusion protein, which includes hemagglutinin and a receptor binding domain of SARS-CoV-2, and a vaccine containing the fusion protein.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

This fusion protein contains a plurality of receptor binding domains from parvovirus, wherein each receptor binding domain is tandemly linked with another such receptor binding domain, either directly or via a peptide linker.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
• A61P 31/12 - Antivirals
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C07K 19/00 - Hybrid peptides
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Provided is a strain that is effective as an active ingredient of a vaccine against betacoronavirus. This SARS-CoV-2 includes non-structural protein(s) that has the following responsible mutation(s): a mutation in the amino acid residue corresponding to the L of position 445 of SEQ ID NO: 1 in NSP3; a mutation in the amino acid residues corresponding to the G of position 248 and the G of position 416 of SEQ ID NO: 2 in NSP14; and/or a mutation in the amino acid residue corresponding to the V of position 67 of SEQ ID NO: 3 in NSP16.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/10 - Transferases (2.)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Strains that is effective as the active component of a vaccine against the betacoronavirus is provided. A SARS-CoV-2 containing structural protein(s) and/or non-structural protein(s) having the following mutation(s): the amino acid residue mutations in NSP3, corresponding to V at position 404, L at position 445, K at position 1792 and/or D at position 1832 in SEQ ID No. 1; the amino acid residue mutations in NSP14, corresponding to G at position 248, G at position 416, and/or A at position 504 in SEQ ID No. 2; the amino acid residue mutation in NSP16, corresponding to V at position 67 in SEQ ID No. 3; the amino acid residue mutations in the spike, corresponding to L at position 54, T at position 739 and/or A at position 879 in SEQ ID No. 4; the amino acid residue mutation in the envelope, corresponding to L at position 28 in SEQ ID No. 5; and/or, the amino acid residue mutation in the nucleocapsid, corresponding to S at position 2 in SEQ ID No. 6;

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention provides a fusion protein which is useful as a vaccine antigen against infectious diseases. A fusion protein according to the present invention, including (a) a combination of hemagglutinin and an N-terminal domain of SARS-CoV-2, (b) a combination of PspA and a receptor binding domain of SARS-CoV-2, (c) a combination of hemagglutinin and respiratory syncytial virus G protein, or (d) a combination of PspA and hemagglutinin, is useful as a vaccine antigen against infectious diseases.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/02 - Bacterial antigens
• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• C07K 14/135 - Respiratory syncytial virus
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C07K 19/00 - Hybrid peptides
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/44 - Orthomyxoviridae, e.g. influenza virus
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

To provide an adjuvant containing lipid particles having a higher immune response inducing ability (preferably, Th1-type immune response inducing ability). This adjuvant contains lipid particles containing a cationic lipid represented by general formula (1).

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 37/04 - Immunostimulants

Abstract

The purpose of the present invention is to provide a strain that is useful as a new betacoronavirus vaccine. A novel betacoronavirus, according to the present invention, having, in combination, a prescribed substitution mutation relating to temperature sensitivity, and a prescribed deletion mutation relating to attenuation, is found to be useful as a betacoronavirus vaccine strain having excellent attenuated characteristics.

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus

Abstract

The present invention provides a new component that is useful as a SARS-CoV-2 vaccine antigen that uses as a target a receptor binding domain of SARS-CoV-2. This fusion protein includes hemagglutinin and a receptor binding domain of SARS-CoV-2. This vaccine includes said fusion protein.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

A strain that is effective as the active component of a vaccine against the beta coronavirus is provided. A SARS-CoV-2 virus containing a structural protein and/or nonstructural protein having the following mutations: the amino acid residue mutation in NSP3, corresponding to V at position 404, L at position 445, K at position 1792 and/or D at position 1832 in SEQ ID No. 1; the amino acid residue mutation in NSP14, corresponding to G at position 248, G at position 416, and/or A at position 504 in SEQ ID No. 2; the amino acid residue mutation in NSP16, corresponding to V at position 67 in SEQ ID No. 3; the amino acid residue mutation in the spike, corresponding to L at position 54, T at position 739 and/or A at position 879 in SEQ ID No. 4; the amino acid residue mutation in the envelope, corresponding to L at position 28 in SEQ ID No. 5; and/or, the amino acid residue mutation in the nucleocapsid, corresponding to S at position 2 in SEQ ID No. 6;

IPC Classes  ?

• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C07K 14/115 - Paramyxoviridae, e.g. parainfluenza virus
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 7/08 - Inactivation or attenuationProducing viral sub-units by serial passage of virus
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C12N 15/55 - Hydrolases (3)
• C12Q 1/6869 - Methods for sequencing

Abstract

Provided is a strain that is effective as an active ingredient of a vaccine against a betacoronavirus. This SARS-CoV-2 virus includes a non-structural protein that has the following responsible mutation(s): a mutation in the amino acid residue corresponding to the L of position 445 of SEQ ID NO: 1 in NSP3; a mutation in the amino acid residues corresponding to the G of position 248 and the G of position 416 of SEQ ID NO: 2 in NSP14; and/or a mutation in the amino acid residue corresponding to the V of position 67 of SEQ ID NO: 3 in NSP16.

IPC Classes  ?

• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C07K 14/115 - Paramyxoviridae, e.g. parainfluenza virus
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 7/08 - Inactivation or attenuationProducing viral sub-units by serial passage of virus
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
• C12N 15/45 - Paramyxoviridae, e.g. measles virus, mumps virus, Newcastle disease virus, canine distemper virus, rinderpest virus, respiratory syncytial viruses
• C12N 15/55 - Hydrolases (3)
• C12Q 1/6869 - Methods for sequencing

Abstract

The present invention provides a corona virus that has restricted replication characteristics, in that it cannot replicate in normal host cells but can replicate in special host cells. The knockout coronavirus has lost at least some of the function of a replication-related gene on the coronavirus genomic RNA, and is unable to replicate in a host cell that lacks the replication-related gene while having the capacity to replicate in a host cell that contains the replication-related gene.

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

The present invention addresses the problem of providing a preventive agent for Japanese encephalitis and a Japanese encephalitis vaccine that are capable of giving humans adequate immunity even with a dose smaller than that for a subcutaneously-administered Japanese encephalitis vaccine or with fewer administrations as compared to the number of administrations of a subcutaneously-administered Japanese encephalitis vaccine. The present invention provides a preventive agent for Japanese encephalitis, which includes a microneedle array that comprises a sheet and a plurality of needles disposed on the top surface of said sheet, the needles being configured to either include or carry thereon inactivated Japanese encephalitis virus.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus

Abstract

Provided is a production method for reassortant influenza virus having genome segments of two or more kinds of influenza virus in the case where an antigenic strain and donor strain have similar antigenicities. The production method makes use of the first influenza virus containing an antigenic protein, the second influenza virus having an antigenic protein having antigenicity similar to that of the strain, and the third influenza virus having an antigenic protein having antigenicity different from that of the strain, and includes the steps of: coculturing the strain and the strain by infecting a host therewith, to produce reassortant influenza viruses; selecting influenza virus having the antigenic protein from the viruses; then coculturing the strain and the selected strain by infecting a host therewith; and selecting influenza virus having the antigenic protein from reassortant influenza viruses produced from the strain and the strain.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial cell component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial cell component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Provided is a botulinum toxin producing method which is simple achieves a high toxin yield, and obtains a toxin having high specific activity. This botulinum toxin producing method includes: (A) a step in which a botulinum toxin is produced from botulinum toxin-producing bacteria in a medium, and a mixture a is obtained which contains a botulinum toxin, a bacterial cell component, and a nucleic acid component derived from the botulinum toxin; (B) a step in which the mixture a is subjected to the removal of the bacterial cell component, and a mixture b is obtained which contains a nucleic acid component and a botulinum toxin; (C) a step in which an endonuclease is added to the mixture b and a mixture c is obtained which contains a nucleic acid degradation product and a botulinum toxin; and (D) a step in which the mixture c is subjected to removal of the nucleic acid degradation product, and an isolated botulinum toxin liquid d is obtained.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

[Problem] To provide a CHO cell line for producing a viral structural protein having a higher-order structure. [Solution] A CHO cell line for producing a viral structural protein having a higher-order structure, said CHO cell line having an expression vector, which contains a gene encoding the structural protein and a promoter connected in an operable manner to the gene, introduced thereinto.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 15/41 - Picornaviridae, e.g. rhinovirus, coxsackie viruses, echoviruses, enteroviruses
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention addresses the problem of providing an antigen for generating an antibody for inhibiting infection of multiple types of HuNov, a use thereof, and an antibody for inhibiting infection of multiple types of HuNov. Specifically, the present invention provides: a method for producing an antibody for inhibiting infection of different genotypes of human norovirus (HuNoV) to intestinal epithelial cells, comprising immunization using the full length or a part of VP1 protein of GII.17 HuNoV as an antigen; and an antibody for inhibiting infection of a plurality of different genotypes of HuNoV to intestinal epithelial cells.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/12 - Viral antigens
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 31/14 - Antivirals for RNA viruses
• C12N 15/13 - Immunoglobulins

Abstract

Provided is a method for culturing the influenza virus using MDCK cells as a host, wherein the influenza virus is cultured more efficiently. The influenza virus is inoculated under protease-free medium conditions after the MDCK cells have passed the logarithmic growth phase. Aggregation and damage of MDCK cells by protease can be prevented, and the influenza virus can be cultured efficiently. In addition, a higher yield of viral protein is expected than when the influenza virus is grown using chicken eggs as the host.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Problem: To provide a multi-layer culture vessel observation system, a carriage device and a multi-layer culture vessel observation device, with which it is possible for an operator to easily observe a to-be-observed object in a multi-layer culture vessel. Solution: A multi-layer culture vessel observation system comprising: a movable carriage device 20 in which a multi-layer culture vessel 30 having a plurality of built-in trays is installed; and an observation device 10 which allows a to-be-observed object in the trays of the multi-layer culture vessel 30 to be observed, wherein: the carriage device 20 includes a frame comprising a side surface exposure part which exposes, from top to bottom, two side surfaces faced by the multi-layer culture vessel 30; the observation device 10 includes an accommodation part 14 which accommodates the carriage device 20 with the multi-layer culture vessel 30 installed therein, and an image pick-up device 11 which comprises an optical system and outputs an image formed by said optical system; and when the carriage device 20 in which the multi-layer culture vessel 30 is installed is accommodated in the accommodation part 14, the side surface exposure part is positioned on the optical axis of the image pick-up device 11.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/32 - Inoculator or sampler multiple field or continuous type

Abstract

The present invention provides a substance which is useful as a carrier for protein purification. Since an aluminum phosphate compound that is obtained by a method for producing an aluminum phosphate compound, which comprises a step for obtaining a mixture that contains an aluminum phosphate compound by mixing an aqueous solution A containing phosphate ions with an aqueous solution B containing aluminum ions, sulfate ions and at least either potassium ions or magnesium ions, exhibits excellent protein adsorption properties, this aluminum phosphate compound is useful as a carrier for protein purification.

IPC Classes  ?

• C01B 25/36 - Aluminium phosphates
• B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating

Abstract

The present invention addresses the problem of providing a Japanese-encephalitis-vaccine-containing microneedle array in which it is possible to suppress a decrease in the activity of the Japanese encephalitis vaccine during production of a microneedle array. The present invention provides a microneedle array having a sheet part and a plurality of needle parts present on the upper surface of the sheet part, wherein: the needle parts contain an electrically neutral water-soluble polymer and/or disaccharide, Japanese encephalitis vaccine, and an electrically neutral surfactant; and the sheet part contains an electrically neutral water-soluble polymer and/or disaccharide.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 14/36 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from ActinomycesPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptomyces (G)
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C07K 19/00 - Hybrid peptides
• A61P 37/04 - Immunostimulants
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12N 15/09 - Recombinant DNA-technology

Abstract

in vitroin vitro, the method avoiding the moral issues involved with conventional methods and the need to treat cells with bile. Specifically, the present invention relates to: a method for proliferating HuNoV, the method including a step for infecting an intestinal epithelial cell derived from a human iPS cell with HuNoV, and a step for culturing said intestinal epithelial cell; and a screening method for a HuNoV-proliferation inhibitor using said method.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides a vaccine for enteroviruses. In view of the structure of enteroviruses, particularly VP0's cleaving VP2 and VP4, it was discovered that said cleaving affects immunogenicity. In other words, it is believed that designing a vaccine including a large amount of VP2 and VP4 as polypeptides which exhibit immunogenicity leads to providing a vaccine which exhibits high immunogenicity. Polypeptides including VP1, VP2, VP3, and VP4 derived from an enterovirus are produced, and these polypeptides are confirmed to have a high effect as an immunogen against enteroviruses.

IPC Classes  ?

• C07K 14/085 - Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
• A61K 39/125 - Picornaviridae, e.g. calicivirus
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/04 - Inactivation or attenuationProducing viral sub-units
• C12N 9/50 - Proteinases

Abstract

Provided is a method for constructing a reassortant influenza virus that has genomic segments of at least two types of influenza virus when an antigen strain and a donor strain have analogous antigenicity. The method relies upon a step for using (1) a first influenza virus containing an antigen protein (x), (2) a second influenza virus containing an antigen protein (x') having antigenicity analogous to that of strain (1), and (3) a third influenza virus containing an antigen protein (y) having antigenicity different from that of strain (1) to infect hosts with strain (2) and strain (3) and co-culture to construct reassortant influenza viruses, and selecting an influenza virus (Y) comprising the antigen protein (y) from among said viruses, followed by infecting hosts with strain (1) and the selected strain (Y), co-culturing, and selecting an influenza virus (X) comprising the antigen protein (x) from the reassortant influenza viruses constructed from strain (1) and strain (Y).

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material

Abstract

Provided is a method whereby a sterilized viscous base can be easily produced at a high sterilization efficiency. The method for producing a sterilized viscous base (base no. 5) comprises: a heat sterilization step for heat sterilizing an acidic solution of a viscosity-imparting agent (base no. 2) which shows a higher viscosity in a neutral range than in an acidic range; and a neutralization step for, after the heat sterilization step, neutralizing the heat sterilized product (base no. 3) of the acidic solution of the viscosity-imparting agent by adding a base thereto.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 37/04 - Immunostimulants

Abstract

The present invention addresses the problem of providing a polyvalent vaccine that is capable of inducing immunity against two or more kinds of microorganisms including Clostridium perfringens and also providing a medicinal composition that is capable of efficiently preventing and/or treating infectious disorders. To solve this problem, provided is a polyvalent vaccine characterized by comprising, as active ingredients, a C-terminal fragment of C. perfringens enterotoxin (C-CPE) and at least one antigen derived from a microorganism other than C. perfringens and being capable of inducing immunity against two or more kinds of microorganisms including C. perfringens. In the polyvalent vaccine according to the present invention, the C-CPE and the at least one antigen form together a fusion so that the capability of inducing immunity against two or more kinds of microorganisms including C. perfringens can be exerted.

IPC Classes  ?

• A61K 39/116 - Polyvalent bacterial antigens
• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 39/106 - VibrioCampylobacter
• A61K 39/108 - EscherichiaKlebsiella
• A61P 37/04 - Immunostimulants

Abstract

Provided is lipid A, which has a novel structure. More specifically, provided is lipid A which can be used in an adjuvant, and with which side effects such as allergic reaction and inflammation are reduced, while maintaining an excellent immunological activation ability. Also provided is an adjuvant composition including lipid A. Lipid A is characterized by comprising a complex of a glucosamine disaccharide chain and fatty acid chains. Lipid A is further characterized in that: 3-hydroxy fatty acid chains are bonded to positions 2 and 2' of the glucosamine disaccharide chain; and a secondary fatty acid chain comprising a 3-hydroxy fatty acid chain is further bonded to at least one of the 3-hydroxy fatty acid chains. The adjuvant including lipid A inhibits side effects such as allergic reaction and inflammation, while maintaining excellent immunological activation action in comparison to adjuvants known in the prior art.

IPC Classes  ?

• C12P 19/00 - Preparation of compounds containing saccharide radicals
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 37/04 - Immunostimulants
• C07H 13/06 - Fatty acids

Goods & Services

Pharmaceutical preparations; biological preparations for medical purposes; vaccines.

Goods & Services

Pharmaceutical preparations; biological preparations for medical purposes; vaccines.

Abstract

The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
• A61P 37/04 - Immunostimulants
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• C07K 19/00 - Hybrid peptides
• C12N 15/09 - Recombinant DNA-technology
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The purpose of the present invention is to provide: an adjuvant composition which is highly safe and can effectively improve a protective immunity induced by a vaccine; and a vaccine preparation utilizing the adjuvant composition. A CpG oligodeoxynucleotide is selected among from adjuvants, and the CpG oligodeoxynucleotide is used in combination with carbonate apatite. The adjuvant composition is highly safe and can effectively improve a protective immunity induced by a vaccine.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient

Abstract

Provided is a method for producing a reassortant influenza virus having genome segments from two or more influenza virus strains. This method for producing a reassortant influenza virus containing an antigen protein from a first influenza virus strain comprises the following steps: 1) A step in which the first influenza virus strain is irradiated with ultraviolet rays at a dose at which the virus has reduced or no proliferation capacity and maintains initial infectivity; 2) a step in which a host is infected with the first influenza virus strain and a second influenza virus strain; 3) a step in which the host infected with the first influenza virus strain and the second influenza virus strain is cultured to obtain a culture; 4) a step in which, from the culture obtained at step 3), an influenza virus strain having an antigen protein of the second influenza virus strain is deactivated; and 5) a step in which a reassortant influenza virus is recovered following step 4).

IPC Classes  ?

• C12N 7/02 - Recovery or purification
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus

Abstract

The present invention pertains to: cloned MDCK cells which exhibit an expansion factor of 4.5-fold or more when being cultured using microcarriers; a method for culturing the MDCK cells; and a method for multiplying a virus by using the MDCK cell culturing method.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to a purification method for target protein, using a layered double hydroxide represented by general formula (I) below. General formula (I): [M2+1-xM3+x(OH)2][An-x/n・mH2O] (In general formula (I) above: M2+ and M3+ are a divalent metal and a trivalent metal, respectively; An- is an interlayer anion; x is given by [M3+]/（[M2+]＋[M3+]; and x is 0.1-0.9, n is 1-3, and m is 0-100).

IPC Classes  ?

• C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/04 - Immunostimulants
• B01D 15/04 - Separating processes involving the treatment of liquids with solid sorbentsApparatus therefor with ion-exchange materials as adsorbents
• B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group

Abstract

Provided are: a vaccine pharmaceutical composition for oral administration, capable of stably storing an influenza virus antigen; and a method for manufacturing the pharmaceutical composition. The vaccine pharmaceutical composition for oral administration is characterized by containing an influenza virus antigen, an excipient, a disaccharide, and an amino acid.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention pertains to a method for measuring complement-dependent bactericidal function with respect to pneumococci, and provides a method for measuring activity which can perform measurements with respect to all capsular serotypes of pneumococcus. This method employs the measurement of complement-dependent bactericidal function with respect to pneumococci, using capsule deleted pneumococci, that is to say noncapsular or close to noncapsular, or transparent pneumococci. With this method it is possible to measure complement-dependent bactericidal function with respect to all capsular serotypes of pneumococcus.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/15 - Medicinal preparations
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• C12N 1/20 - BacteriaCulture media therefor
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/0787 - Granulocytes, e.g. basophils, eosinophils, neutrophils or mast cells

Abstract

Provided is an antigen composition, pertaining to human herpes virus 6B (HHV-6B), which can be stably supplied in a large amount. Also provided is a vaccine including this antigen composition. Also provided is a method for producing this antigen composition. HHV-6B antigen tetrameric complexes including gH, gL, gQ1, and gQ2 among the surface proteins of HHV-6B are used as the antigen composition. The HHV-6B antigen tetrameric complexes make it possible to provide an antigen composition which can be stably supplied in a large amount. Because the antigen composition can be stably supplied in a large amount, it is possible to stably supply vaccines and pharmaceutical compositions including this antigen composition, which is industrially advantageous.

IPC Classes  ?

• C07K 14/03 - Herpetoviridae, e.g. pseudorabies virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• A61P 37/04 - Immunostimulants
• C07K 19/00 - Hybrid peptides
• C12N 15/09 - Recombinant DNA-technology

Abstract

The invention pertains to MDCK cells that can be used suitably in influenza virus production. In particular, it pertains to MDCK cells for influenza virus production having excellent influenza virus production efficiency without coculture with other species of cells. It also pertains to a method for producing an influenza virus characterized by using these MDCK cells.

IPC Classes  ?

• C12N 5/07 - Animal cells or tissues
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention relates to an adjuvant, which is a layered double hydroxide and is obtained from a compound represented by general formula (I) in the Specification. Because the layered double hydroxides in the present invention are conjugates with an inorganic ion selected from light metals, it is thought that adverse reactions of a living body when an immune composition comprising an adjuvant according to the present invention is administered to the living body will be minimal. Because there are countless combinations of divalent cations, trivalent cations and anions in layered double hydroxides, it is possible to manufacture a layered double hydroxide suited to the use thereof.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/05 - CorynebacteriumPropionibacterium
• A61K 39/08 - Clostridium, e.g. Clostridium tetani
• A61K 39/09 - Streptococcus
• A61K 39/10 - BrucellaBordetella, e.g. Bordetella pertussis
• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/29 - Hepatitis virus
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 37/04 - Immunostimulants

Abstract

　The purpose of the present invention is to provide a novel antibody having high avidity and high neutralizing activity with respect to an influenza virus. The present invention provides an antibody for neutralizing the H1-type influenza virus and/or the H5-type influenza virus, which have: a heavy chain variable region having a CDR composed of a specific heavy chain first complementarity determining region (VH-CDR1), a heavy chain second complementarity determining region (VH-CDR2), and a heavy chain third complementarity determining region (VH-CDR3); and a light chain variable region having a CDR composed of a specific light chain second complementarity determining region (VL-CDR2), and a light chain third complementarity determining region (VL-CDR3).

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/08 - Monoclonal antibodies

Abstract

Materials and methods are provided for detecting, preventing, and treating dengue virus infections and symptoms. Antigenic peptides, isolated nucleic acids encoding such peptides, reagents containing such peptides, reagent kits, and method of detections are provided. Vaccines are provided that contain one or more antigenic peptides based on the first domain II of a dengue virus (DENV) envelope protein (EDII). These vaccines are capable of stimulating a dengue virus immunological response in a subject previously infected with a dengue virus. Methods of manufacturing such vaccines are also presented. Further provided are methods of administering such vaccines to vaccinate a subject that has or has not been previously infected with a dengue virus.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by lowpH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HAl and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C12N 15/02 - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
• C12P 21/08 - Monoclonal antibodies
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Materials and methods are provided for treating dengue infections. Human monoclonal antibodies against all serotypes of dengue virus are also provided. Methods of using human monoclonal antibodies to neutralize all dengue-virus serotypes are provided using patients' peripheral blood lymphocytes.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention addresses the problem of providing a vaccine which as yet has not been provided for the disease HHV-6B, which is the cause of exanthema subitum in infants, and the problem of providing an effective screening method for other therapeutic drugs. The above-mentioned problems are solved by providing an epitope specific to HHV-6B, wherein, of the amino acid sequence (QALCEGGHVFYNP) represented by positions 484 to 496 of SEQ ID NO: 2 or a modified sequence thereof, the epitope either has a sequence comprising at least five consecutive amino acids including at least E, or a sequence that preserves the 487th C and 489th G when E is changed to Q.

IPC Classes  ?

• C07K 14/03 - Herpetoviridae, e.g. pseudorabies virus
• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C12N 15/09 - Recombinant DNA-technology
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention provides an anti-influenza virus antibody that has neutralizing activity against any of the influenza viruses which are categorized into two groups by degree of amino acid conservation in hemagglutinin, regardless of any differences between the groups. The present invention also provides a method for producing the same, and a method for testing whether a subject has the neutralizing antibody.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention addresses the problem of establishing a method for predicting onset risk of herpes zoster against which the acquisition or lack of immunity can be exclusively examined so far. A method for predicting the onset risk of herpes zoster in future which comprises employing, as a standard, at least one factor selected from among the major diameter of an edema, the outer circumferential length of an erythema and the average erythema diameter.

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Goods & Services

Pharmaceutical, veterinary and sanitary preparations, other than pyrethrum coils and other anti-mosquito incenses and fragrances, medicated soaps of Japanese pharmacopoeia, and medicated alcoholic beverages.

Abstract

Disclosed is an enhancer for a viral promoter such as a promoter that can induce expression selectively and strongly in immunocompetent cells (e.g., lymphocytes) or blood cells. It is found unexpectedly that an intron has the above-mentioned enhancer activity. Thus, it is found that an enhancer for a promoter, which comprises an intron sequence for a major immediate early gene (MIE) of human herpes virus-6 (HHV-6) (particularly HHV-6B) or a fragment of the intron sequence, has a potent promoter activity.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Goods & Services

(1) Pharmaceutical, veterinary and sanitary preparations (other than pyrethrum coils and other anti-mosquito incenses and fragrances, and medicated soaps of Japanese Pharmacopoeia), namely human vaccines, veterinary vaccines, antibodies for biopharmaceutical purposes; biological preparations for treating Influenza, Japanese Encephalitis, Measles virus, Rubella virus, Varicella virus, human Papilloma virus, Diptheria, Tetanus and Pertussis.

Abstract

Antigenic peptides are provided that can be used to induce global neutralizing antibodies, or antibodies reactive against a wide range of influenza A virus strains. The antigenic peptide can correspond to SEQ ID NO: 34 (EKEVLVLWG), SEQ ID NO: 2 (KFDKLYIWG), SEQ ID NO: 71(QEDLLVLWG), SEQ ID NO: 51 (EGRINYYWTLLEP), SEQ ID NO: 3 (PSRISIYWTIVKP), and/or SEQ ID NO: 82 (SGRMEFFWTILKP).

IPC Classes  ?

• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present invention provides a vaccine composition for transnasal mucous membrane administration, which contains an influenza virus antigen, polyriboinosinic polyribocytidylic acid (poly (I:C)) or a derivative thereof and a carboxyvinyl polymer. The present invention also provides a prophylactic method of influenza, including a step of administering the vaccine composition at least once to the nasal mucosa of a subject in need thereof.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus

Abstract

Disclosed is a human antibody having a neutralization activity against a human influenza virus. Specifically disclosed is a human antibody which can recognize a highly conserved region in a human influenza A virus subtype H3N2 and a human influenza B virus and has a neutralization activity against the virus. More specifically disclosed is a human anti-human influenza virus antibody which has a neutralization activity against a human influenza A virus subtype H3N2 and is capable of binding to a hemagglutinin HA1 domain in a human influenza A virus subtype H3N2 or which has a neutralization activity against a human influenza B virus, wherein the nucleotide sequence of DNA that encodes a variable region of the antibody comprises any one sequence selected from those depicted in SEQ ID NO:5 to SEQ ID NO:12.

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 15/09 - Recombinant DNA-technology

Abstract

Disclosed are: a signal peptide for secreting/producing a virus-like particle (VLP) at a high level, which comprises a modified product of a signal sequence derived from a West Nile virus (WNV); an expression vector for secreting a WNV VLP, which comprises a nucleic acid encoding the signal peptide, a nucleic acid encoding prM protein and a nucleic acid encoding E protein; an animal cell line capable of secreting/producing a WNV VLP at a high level, which has the vector introduced therein; a WNV vaccine comprising, as an active ingredient, a WNV VLP produced by using the cell line; and a WNV DNA vaccine comprising, as an active ingredient, the expression vector for secreting the VLP.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 39/12 - Viral antigens
• A61P 31/12 - Antivirals
• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Disclosed are a cancer antigen peptide vaccine and an adjuvant for a virus antigen peptide, each of which comprises a pertussis vaccine as the main ingredient. Also disclosed is an agent for the treatment of cancer or a viral infection or for the prevention of the metastasis or recurrence of cancer or a virus-induced tumor, which comprises a cancer antigen peptide or a virus antigen peptide and a pertussis vaccine. A whole cell pertussis vaccine can be particularly preferably used as the pertussis vaccine. The agent is safe for multiple times of administration.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/102 - PasteurellaHaemophilus
• A61K 39/12 - Viral antigens
• A61K 39/29 - Hepatitis virus
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• C07K 14/235 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bordetella (G)
• C07K 14/82 - Translation products from oncogenes

Abstract

It is intended to contribute to the elucidation of the mechanism of postzoster neuralgia and to provide means for promoting the regeneration of damaged nerve. Further, it is intended to provide means which is effective in the prevention or treatment of a disorder caused by neuronal cell death accompanying postzoster neuralgia, chronic pain, postherpetic neuralgia, apoplexy, a degenerative disease or the like, or any of the above diseases, and has fewer side effects. A neurite elongation promoter comprising an antibody that recognizes a varicella-zoster virus immediate-early protein and crossreacts with a brain-derived neurotrophic factor as an active ingredient; a preventive or therapeutic agent for a neurogenic disease comprising the antibody as an active ingredient; a neurite elongation inhibitor comprising an inhibitory antibody that recognizes a varicella-zoster virus immediate-early protein and inhibits a brain-derived neurotrophic factor as an active ingredient; and a preventive or therapeutic agent for a disease accompanied by neural hypersensitivity caused by a condition selected from the group consisting of postzoster neuralgia, chronic pain, experience-dependent social aversion and stress, comprising the inhibitory antibody as an active ingredient.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 21/04 - Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 35/00 - Antineoplastic agents
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses

Abstract

Disclosed are: a precipitated/inactivated whole virus influenza vaccine which can effectively act on a new-type influenza virus, particularly a new-type virus having low immunogenicity, at a low amount of antigen and which has little adverse side-effects; and a method for producing the vaccine. Specifically disclosed are: a precipitated/inactivated influenza vaccine comprising an aluminum hydroxide gel prepared from sodium carbonate and aluminum potassium sulfate and an isolated whole influenza virus particle as active ingredients; and a method for producing the precipitated/inactivated influenza vaccine, which is characterized by conducting each step by using a solvent containing no surfactant or no ether.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

To supply an influenza vaccine having an enhanced effect, it is intended to provide an adjuvant which enables the potentiation of both of humoral immunity and cellular immunity, and an influenza vaccine using the same. As a means for resolution, an adjuvant for an influenza vaccine which comprises biodegradable nanoparticles having a polyamino acid as the skeleton thereof and an influenza vaccine which contains an influenza virus antigen and the adjuvant as described above are provided. As the polyamino acid, one having poly(γ-polyglutamic acid) as the main constituent is preferred.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Disclosed are recombinant varicella-zoster virus, a process for producing the virus, a pharmaceutical composition comprising the recombinant varicella-zoster virus, a vector having a BAC vector sequence in a specific gene of the varicella-zoster virus genomic gene, a cell having the vector therein, a fragment capable of homologous recombination with the varicella-zoster virus genome, a nucleic acid cassette comprising a BAC vector sequence, and a polyvalent vaccine. A process for producing a recombinant varicella-zoster virus having a BAC vector sequence inserted in a specific viral gene.

IPC Classes  ?

• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• A61K 39/25 - Varicella-zoster virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• A61P 37/04 - Immunostimulants
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

A therapeutic agent for cancer comprising, as an active ingredient, a substance capable of binding to HB-EGF to thereby inhibit the binding between HB-EGF and an EGF receptor (particularly CRM197), the cancer being selected from the group consisting of bladder cancer, colorectal cancer or disseminated peritoneal metastatic cancer from gastric cancer and pancreatic cancer.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Goods & Services

(1) Pharmaceutical preparations, diagnostic preparations and biological products for human and animal use, namely: rubella vaccine, influenza vaccine, mumps vaccine, cholera vaccine, diphtheria antitoxin, diptheria toxoid, mixed diphtheria/tetanus toxoid, smallpox vaccine, Japanese encephalitis vaccine, tetanus antitoxin, tetanus toxoid, mixed pertussis/diphtheria vaccine, mixed pertussis/diphtheria/tetanus vaccine, measles vaccine, agkistrodon antitoxin, pertussis vaccine, measles virus antigen for diagnosis, Japanese encephalitis virus antigen for diagnosis, rubella virus antigen for diagnosis, mumps virus antigen for diagnosis, complement, typhys vaccine, equine antiserum against human serum, hemolysin, varicella vaccine, mixed measles/mumps/rubella vaccine, hepatitis B vaccine, varicella antigen, marek's disease vaccine, porcine parvovirus vaccine, gumboro disease vaccine, acquired immunodeficiency syndrome vaccine, human immunodeficiency virus antigen for diagnosis, non-A, non-B hepatitis vaccine, non-A, non-B hepatitis antigen for diagnosis, non-A, non-B hepatitis DNA probe for diagnosis, hemorrhagic fever with renal syndrome virus vaccine, hemorrhagic fever with renal syndrome virus antigen for diagnosis.